☰ Menu
× Close

Pipeline

The $88B in-vitro diagnostic global market is a diverse, growing and technology driven sector. 1 Up to 70% of all healthcare decisions are made leveraging the insights obtained from lab tests. 2 Our company’s mission is to provide innovative diagnostic tests that enable earlier detection, risk stratification and monitoring of challenging diseases. The company’s technology platform is versatile and adaptable to enable innovative assay panels across multiple sectors of the in-vitro diagnostic market including cancer and other challenging diseases. The BioMatra platform has many applications beyond pancreatic cancer and our lead assay PanCystPro. The team has developed research assays in infectious disease, kidney disease, and other cancers. To learn more about our research and applications in pancreatic cancer and beyond, be sure to check out our publications and follow us on LinkedIn.

Patent Information

Interested in partnering with us or leveraging our BioMatra platform for your research interests?

Contact Us

REFERENCES:

  1. https://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html#:~:text=The%20global%20in%20vitro%20diagnostics,trend%20analysis%20of%20the%20market.
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759162/#:~:text=The%20often%20stated%20claim%20that,test%20results%2C%20both%20in%20the